Suicidality and second generation anytipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Rates of attempted suicide for individuals with schizophrenia are approaching 30%. Attempted suicide is among the most potent predictors of subsequent suicide. Several studies suggest that suicide is more likely to occur in patients who are not being adequately treated or not being treated at all. An effort was made in the last decade to evaluate the antisuicide effects of pharmacological treatment in schizophrenia with emphasis on the role of the newer second-generation antipsychotics (SGA).
The aim of the present study was to assess in a large cohort of schizophrenia patients the effects of exposure to SGA on suicidality of patients suffering from schizophrenia or schizoaffective disorder. The study is a retrospective case-controlled evaluation over a 5-year period undertaken in a large university affiliated tertiary care psychiatric hospital.
Between January 1998 and December 2002, all records of admissions of schizophrenia or schizoaffective disorder patients (ICD-10) were assessed. Data as to age, gender, diagnosis, suicide attempt prior to admission, treatment with antipsychotic medication, dose and duration of treatment (mg daily, duration) with SGA was extracted from patients’ files. All patients who had attempted suicide prior to admission were defined as the index group. The case-controlled group was comprised of the next admission of a patient suffering from schizophrenia (or schizoaffective disorder), matched for gender and age, who did not attempt suicide.
Records of 756 patients (4486 admissions for said period) were analyzed (56.6% male, mean age 39.1±13.5 years). Amongst 378 patients who attempted suicide (index group), 16.1% were exposed to SGA while 37% were exposed in the control group (P=0.0001). The protective effect (odds ratio) of treatment by SGA was 3.54 (95%CI: 2.4–5.3). Risperidone was more frequently prescribed in the control group (54.3%) and had a larger effect-size than olanzapine (3.16 versus 1.76), although not statistically significant. Clozapine was prescribed only to a few patients.
Schizophrenia patients exposed to both risperidone and olanzapine may gain protection from suicidality. The antisuicide effects seem to differ between SGAs. The long duration and large sample size support this finding, despite the retrospective nature of this study.
- Aleman A, Kahn RS (2001) Effects of the atypical antipsychotic risperidone on hostility and aggression in schizophrenia: a meta-analysis of controlled trials. Eur Neuropsychopharmacol 11:289–293 CrossRef
- Allebeck P (1989) Schizophrenia: a life-shortening disease. Schizophr Bull 15:81–89
- Altamura AC, Bignotti S, Pioli R, Tura G, Mannu P, Soddu A, La Croce L (1999) Suicidal behavior in schizophrenia: a retrospective study. Eur Neuropsychopharmacol 9:S271
- Altamura AC, Bassetti R, Bignotti S, Pioli R, Mundo E (2003) Clinical variables related to suicide attempts in schizophrenic patients: a retrospective study. Schizophr Res 60:47–55 CrossRef
- Caldwell C, Gottesman I (1990) Schizophrenics kill themselves too: a review of risk factors for suicide. Schizophr Bull 16:571–589
- Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B (2001) Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia. Am J Psychiatry 158:518–526
- Ciapparelli A, Dell’Osso L, Pini S, Chiavacci MC, Fenzi M, Cassano GB (2000) Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study. J Clin Psychiatry 61:329–334
- Conley RR, Mahmoud R (2001) A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. Am J Psychiatry 158:765–774 CrossRef
- De Hert M, McKenzie K, Peuskens J (2001) Risk factors for suicide in young people suffering from schizophrenia: a long-term follow-up study. Schizophr Res 47:127–134 CrossRef
- Duggan A, Warner J, Knapp M, Kerwin R (2003) Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry 182:505–508 CrossRef
- FDA (2003) Clozaril approved for reducing risk of suicide. FDA Consum 37:5
- Fleischhacker WW, Oehl MA, Hummer M (2003) Factors influencing compliance in schizophrenia patients. J Clin Psychiatry 64:10–13
- Foster RH, Goa KL (1999) Olanzapine:a pharmacoeconomic review of its use schizophrenia. Pharmacoeconomics 15:61–640
- Glazer WM (1998) Formulary decisions and health economics. J Clin Psychiatry 59:23–29
- Heilä H, Isometsa ET, Henrikkson MM, Heikkinen ME, Marttuneen MJ, Lonqvist JK (1997) Suicide and schizophrenia: a nationwide psychological autopsy study on age- and sex-specific clinical characteristics of 92 suicide victims with schizophrenia. Am J Psychiatry 154:1235–1242
- Herings RMC, Erkens JA (2003) Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Safety 12:423–424 CrossRef
- Jibson MD, Tandon R (2000) Treatment of schizophrenia. Psychiatr Clin N Am 7:83–113
- Keck Jr PE, Strakowski SM, McElroy SL (2000) The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry 61:4–9
- Khan A, Khan SR, Lenthal RM, Brown WA (2001) Symptom reduction and suicide risk among patients treated with placebo in antipsychotic clinical trials: an analysis of the Food and Drug Administration database. Am J Psychiatry 158:1449–1454 CrossRef
- Marder SR (2003) Overview of partial compliance. J Clin Psychiatry 64:3–9
- Mauskopf J, Muroff M, Gibson PJ, Grainger DL (2002) Estimating the costs and benefits of new drug therapies: atypical antipsychotic drugs for schizophrenia. Schizophr Bull 28:619–635
- Meltzer HY (2001) Treatment of suicidality in schizophrenia. Ann N Y Acad Sci 932:44–58
- Meltzer HY (2002) Suicidality in schizophrenia: a review of the evidence for risk factors and treatment options. Curr Psychiatr Rep 4:279–283
- Meltzer HY, Dev VJ (2002) Suicidality during quetiapine treatment: a risk-benefit assessment. Poster presented in the 155th APA
- Meltzer HY, Alphs L, Altamura AC, Anand R, Bertoli R, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkins S (2003) International suicide prevention trial (InterSePT): reduced suicidality in schizophrenia with clozapine treatment. Arch Gen Psychiatry 59:82–91
- Osby U, Correia N, Brandt L, Ekbom A, Sparen P (2000) Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 45:21–28 CrossRef
- Peuskens J, Van Baelen B, De Smedt C, Lemmens P (2000) Effect of risperidone on affective symptoms in patients with schizophrenia. Int Clin Psychopharmacol 15:343–349
- Robins DA, Regier LN (1991) Psychiatric disorders in America. Free Press, New York, p 50
- SAS/STAT (1990) Users’ guide, version 6, 4th edn, vols 1, 2. SAS Institute, Cary, N.C.
- Sernyak MJ, Desai R, Stolar M, Rosenheck R (2001) Impact of clozapine on completed suicide. Am J Psychiatry 158:931–937
- Tamam L, Ozpoyraz N (2001) Suicide during clozapine treatment: a case report. Isr J Psychiatr Relat Sci 38:127–132
- Tandon R, Jibson MD (2003) Suicidal behavior in schizophrenia: diagnosis, neurobiology, and treatment implications. Curr Opin Psychiatry 16:193–197 CrossRef
- Suicidality and second generation anytipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period
Volume 175, Issue 2 , pp 215-219
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Case-controlled study
- Industry Sectors